# Regeneron Pharmaceuticals, Inc. (REGN) — Q2-2018 Earnings Results

**Report date:** 2018-08-02 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q2-2018

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 7.0%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $5.45 | N/A | +13.06% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. They emphasized ongoing efforts to enhance product offerings.

**Key quotes:**

> We are pleased with our EPS performance this quarter.

> Our focus remains on innovation and expanding our product offerings.

### Guidance Changes

No guidance updates were provided during the earnings call.

### What It Means

Regeneron's strong EPS performance exceeded expectations, contributing to a 7% increase in stock price following the earnings report. The positive surprise indicates effective cost management or strong sales in certain areas, although no revenue figures were disclosed. Investors may view this as a sign of resilience and potential for future growth.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q2-2018_